Latest Breaking News On - டயமண்ட் சாகர் - Page 2 : comparemela.com
Controversial homegrown vaccine risks derailing India s coronavirus vaccine rollout
chicagotribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from chicagotribune.com Daily Mail and Mail on Sunday newspapers.
Controversial homegrown vaccine risks derailing India s rollout - South Florida Sun-Sentinel
sun-sentinel.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sun-sentinel.com Daily Mail and Mail on Sunday newspapers.
What s the debate over India s COVID-19 vaccine?
By
Wednesday Feb 03, 2021
India s domestic vaccine made by Bharat Biotech has been surrounded by controversy
The vaccine was approved for human trials by the Indian government in June last year
When India approved its shot before the completion of final human trials, it fuelled a revolt with many at the frontlines of the pandemic refusing the company’s injection
India has its own vaccine for coronavirus - Covaxin - but majority have shown reluctance in taking the shot.
India s drug regulatory authority
gave the green signal to Bharat Biotech s COVID-19 vaccine for human trials in June last year, making it the first domestic candidate from the country as the number of COVID-19 cases in India crossed 565,000 at the time.
Controversial homegrown vaccine risks derailing India s rollout
orlandosentinel.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from orlandosentinel.com Daily Mail and Mail on Sunday newspapers.
Overcoming vaccine hesitancy the key to a successful Covid-19 inoculation drive
SECTIONS
Share
Synopsis
A week into its Covid-19 vaccination drive, India needs to overcome its vaccine hesitancy that is hobbling efforts.
Agencies
The bigger challenge to tackle hesitancy, though, might well be when the vaccine drive is opened to those beyond frontline workers.
Related
Please do come. There is no queue, it won’t take long,” Akash Kumar Jha says persuasively, as he speaks on the phone to a doctor at New Delhi’s Ram Manohar Lohia Hospital. It’s one of the many calls the hospital’s first officer for vaccination is making on Thursday morning to coax colleagues into coming in and rolling up their sleeves for a shot of Covaxin, one of the two vaccines India has approved to immunise the country against Covid-19. Jha has good reason to be as convincing as possible it had been five days since India launched its vaccine drive but the numbers at RML Hospital were not encourag